Overview

This trial is active, not recruiting.

Condition alpha-1 antitrypsin deficiency
Treatment raav1-cb-haat
Phase phase 2
Sponsor Applied Genetic Technologies Corp
Collaborator National Heart, Lung, and Blood Institute (NHLBI)
Start date March 2010
End date November 2011
Trial size 9 participants
Trial identifier NCT01054339, 2009‐014286‐20, AGTC-AAT-002, R01 FD003896, R01HL069877

Summary

This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing alpha-1 antitrypsin in patients with alpha-1 antitrypsin deficiency. Three groups of three subjects each will receive the study drug by intramuscular injection, with progressively larger doses in the second and third groups.

Funding Sources - FDA OOPD and NIH NHLBI

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
rAAV1-CB-hAAT at dosage level of 6 x 10e11 vg/kg
raav1-cb-haat
Recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin
(Experimental)
rAAV1-CB-hAAT at dosage level of 1.9 x 10e12 vg/kg
raav1-cb-haat
Recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin
(Experimental)
rAAV1-CB-hAAT at dosage level of 6 x 10e12 vg/kg
raav1-cb-haat
Recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin

Primary Outcomes

Measure
Frequency of Grade 3 or 4 Adverse Events
time frame: During 1 year after study agent administration

Secondary Outcomes

Measure
Changes in Serum M-specific Alpha-1 Antitrypsin Concentration
time frame: During months 6-12 after study agent adminsitration
Changes in Serum Total Alpha-1 Antitrypsin Concentrations
time frame: During months 6-12 after study agent adminstration

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: 1. Have a diagnosis of AAT-deficiency, as defined by a serum AAT level of less than 11 µM and a phenotype or genotype either homozygous for PI*Z or compound heterozygous consisting of PI*Z and another allele known to be associated with disease 2. Be at least 18 and not more than 75 years of age 3. Have a FEV1 >25% of predicted value (post bronchodilator) 4. Weigh ≤ 90 kg 5. Not receiving AAT augmentation therapy currently or with the past 3 months, and not planning to begin such therapy for at least 12 months after administration of rAAV1-CB-hAAT 6. Be willing to discontinue aspirin, aspirin-containing products, and other drugs that may alter platelet function, 7 days prior to dosing, resuming no earlier than 24 hours after the dose has been administered 7. Have acceptable laboratory parameters 8. For females of childbearing potential: - A negative pregnancy test (urine or serum) at screening and at baseline (within 2 days before administration of study agent) - Agreement to consistently use barrier contraception (condoms, diaphragm or cervical cap with spermicide) or another form of contraception (e.g. intrauterine device or hormonal contraception) from the screening visit until 12 months after administration of rAAV1-CB-hAAT, for sexual activity that could lead to pregnancy 9. For males of reproductive potential, agreement to consistently use barrier contraception (condoms with spermicide) for 12 months after administration of rAAV1-CB-hAAT, for sexual activity that could lead to pregnancy, 10. Provide signed informed consent before screening Exclusion Criteria: 1. Prior receipt of any AAV gene therapy product 2. Use of anticoagulants or anti-platelet agents within 7 days prior to study agent administration 3. History of immune response to human AAT augmentation therapy as indicated by clinical history of an adverse immune response to infusion and/or decreased therapeutic effect in combination with documentation of serum anti-AAT antibodies 4. Use of acute oral or intravenous antibiotic therapy for a respiratory infection within 28 days prior to study agent administration (long-term maintenance or chronic suppressive oral antibiotics, and antibiotics for a non-respiratory indication, are allowed) 5. Use of oral or systemic corticosteroids within 28 days prior to study agent administration 6. Use of any investigational agent, or any immunosuppressive drug(s), within 3 months prior to enrollment 7. For females of childbearing potential, a positive pregnancy test at screening or baseline (within 2 days before rAAV1-CB-hAAT administration) 8. Females who are breast feeding 9. Have a significant abnormal EKG finding at screening and/or cardiac disease (e.g. recent myocardial infarction or CHF) within past 6 months 10. Have had pulmonary edema or a pulmonary embolism within the past 6 months 11. Have a history of immunodeficiency or other medical condition which leads the investigator to believe that the participant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for participation

Additional Information

Official title A Multiple-Site, Phase 2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Alpha-1 Antitrypsin (rAAV1-CB-hAAT) in Patients With Alpha-1 Antitrypsin Deficiency
Principal investigator Terence R. Flotte, MD
Description The study is a non-randomized, open-label, multi-center, sequential, three-arm, Phase 2 clinical trial evaluating the safety and efficacy of administration of a rAAV1-CB-hAAT vector administered by IM injection. Each participant will receive rAAV1-CB-hAAT on a single occasion. Three groups of three subjects each will receive rAAV1-CB-hAAT at dosage levels of 6 x 10e11 vg/kg, 1.9 x 10e12 vg/kg or 6 x 10e12 vg/kg by IM injection. Subjects in group 1 will receive a total of 10 IM injections distributed across a single muscle site, subjects in group 2 will receive a total of 32 IM injections distributed across three muscle sites, and subjects in group 3 will receive 100 IM injections distributed across 10 muscle sites. Each injection will be given in a volume of 1.35 mL, at the appropriate vector concentration to achieve the desired total vector dose, and the injection density at each administration site (nine IM injections per 4 cm2 skin surface area) will be the same as the injection density that was well tolerated in a previous Phase 1 clinical trial with rAAV1-CB-hAAT. Safety will be monitored by evaluation of adverse events, hematology and clinical chemistry parameters, histological examination of muscle biopsies, and measurement of serum antibodies to AAT. Efficacy will be measured by evaluation of serum concentrations of M-specific AAT and total AAT and serum AAT phenotype determined on isoelectric focusing gels. Additional information to be collected will include presence of the vector in blood or semen, changes in serum anti-AAV antibody titers, and changes in T cell responses to AAV and AAT.
Trial information was received from ClinicalTrials.gov and was last updated in March 2013.
Information provided to ClinicalTrials.gov by Applied Genetic Technologies Corp.